Medication info
DioSartan Tablet 40 mg (Valsartan)

DioSartan Tablet 40 mg (Valsartan)

Prescription medicationTabletOral
Ingredient · strength
Valsartan›40mg / 1 tablet
Manufacturer / importer
Yuhan Corporation
Appearance
Yellow oval-shaped film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 201105486 · Approved 2011.08.23 · Insurance code 642104090

Summary

Main use
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
Who takes it
Adults · Children
Adult dose
1. Essential hypertension Take with water during a meal or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is valsartan 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily, followed over several weeks by dose titration, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is at least 10 mL/min. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Child dose
1. Essential hypertension 6) Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction

  • Essential hypertension
  • heart failure
  • left ventricular dysfunction
  • left ventricular systolic dysfunction
View approved original text

This medication helps control blood pressure in patients with essential hypertension, alleviating symptoms and improving cardiac function in those with heart failure who cannot use ACE inhibitors. It also aids in reducing mortality risk in patients with impaired left ventricular function after a myocardial infarction. Therefore, it plays a crucial role in managing hypertension, heart failure, and post-myocardial infarction care, significantly improving patients' health.

How to take

Adult dose

1. Essential hypertension Take with water during a meal or between meals. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). 1) Adults: Regardless of sex or race, the recommended dose is valsartan 80 mg orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If additional blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. 2) Older adults (75 years and older): Initiate treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, initiate treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily, followed over several weeks by dose titration, taking the patient's tolerability into account, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary when creatinine clearance is at least 10 mL/min. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, because there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild to moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of dose escalation outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.

Child dose

1. Essential hypertension 6) Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: The safety and efficacy of this medicine have not been established in children and adolescents under 18 years of age.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters; if pregnancy is confirmed, it should be discontinued immediately. It is not safe to use this medication in patients with certain conditions. For example, it should not be taken by patients with severe liver disease, significantly impaired kidney function, pregnant women, and those with specific allergic reactions. Elderly patients or those with compromised kidney function, hyperkalemia, etc., require special caution when using this medication, and dosage adjustments or close monitoring of conditions are necessary. During the use of this medication, blood pressure may suddenly drop, causing dizziness or fainting, so extra care is needed, especially when starting treatment or increasing the dosage. This medication may interact with other antihypertensives, diuretics, potassium supplements, etc., so it should be taken only after consulting with a doctor or pharmacist. If symptoms such as muscle pain, skin rash, breathing difficulties, severe dizziness, or low blood pressure appear, medical personnel should be informed immediately. Pregnant or breastfeeding women are advised not to take this medication. If necessary, the decision should be made after consulting a professional. This medication is not recommended for children and adolescents as its safety and efficacy have not been adequately established. In case of overdose, symptoms such as low blood pressure, decreased consciousness, or shock may occur, and immediate emergency treatment is required; do not stop or increase the dosage arbitrarily. Store this medication out of reach of children and do not transfer it to other containers.

Side effects

  • Headache
  • dizziness
  • viral infection
  • upper respiratory tract infection
  • cough
  • diarrhea
  • fatigue
  • rhinitis
  • sinusitis
  • abdominal pain
Show 48 more
  • stomach pain
  • nausea
  • pharyngitis
  • joint pain
  • hypotension
  • orthostatic dizziness
  • orthostatic hypotension
  • renal impairment
  • hyperkalemia
  • angioedema
  • heart failure
  • edema
  • erythema
  • pruritus
  • serum sickness
  • vasculitis
  • syncope
  • epistaxis
  • hepatitis
  • arrhythmia
  • intestinal vascular edema
  • interstitial pneumonia
  • hypoglycemia
  • shock
  • loss of consciousness
  • rhabdomyolysis
  • agranulocytosis
  • leukopenia
  • thrombocytopenia
  • vesicular dermatitis
  • dyspepsia
  • anemia
  • tinnitus
  • tension headache
  • decrease in motor function
  • confusion
  • chest pain
  • rash
  • myalgia
  • edema
  • weakness
  • drowsiness
  • atrial fibrillation
  • vomiting
  • constipation
  • thirst
  • anorexia
  • malaise

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air and moisture from entering and kept in a cool place below 30 degrees Celsius, avoiding direct sunlight or heat. Proper storage helps maintain the drug's efficacy over time.

Appearance and packaging

Appearance

Yellow oval-shaped film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.